Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs
- 3 May 2007
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 50 (7) , 1423-1432
Abstract
Rapamycin, part of the immunosuppressive regimen of the Edmonton protocol, has been shown to inhibit vascular endothelial growth factor (VEGF) production and VEGF-mediated survival signalling in tumour cell lines. This study investigates the survival-promoting activities of VEGF in human islets and the effects of rapamycin on islet viability.Keywords
This publication has 50 references indexed in Scilit:
- Antiangiogenic and Immunomodulatory Effects of Rapamycin on Islet Endothelium: Relevance for Islet TransplantationAmerican Journal of Transplantation, 2006
- Pancreatic Islet Production of Vascular Endothelial Growth Factor-A Is Essential for Islet Vascularization, Revascularization, and FunctionDiabetes, 2006
- Over-expression of AMP-activated protein kinase impairs pancreatic β-cell function in vivoJournal of Endocrinology, 2005
- Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cellsKidney International, 2005
- VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice VariantCancer Research, 2004
- An Adenovirus‐Mediated Gene‐Transfer Model of Angiogenesis in Rat MesenteryMicrocirculation, 2004
- Insulin Independence Following Isolated Islet Transplantation and Single Islet InfusionsAnnals of Surgery, 2003
- Secretory defects induced by immunosuppressive agents on human pancreatic β-cellsActa Diabetologica, 2002
- VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED IN DEVASCULARIZED RAT ISLETS OF LANGERHANS IN VITRO1Transplantation, 1997
- The Efficacy And Toxicity Of Rapamycin In Murine Islet TransplantationTransplantation, 1993